NYSE:NGVTIngevity Stock Price, Forecast & News

$57.88

+1.58 (+2.81 %)

(As of 06/3/2020 04:00 PM ET)

Add

Compare

Today's Range

$57.25

Now: $57.88▼

$59.80

50-Day Range

$37.70

MA: $46.01▼

$57.80

52-Week Range

$24.92

Now: $57.88▼

$108.20

Volume492,880 shs

Average Volume416,831 shs

Market Capitalization$2.39 billion

P/E Ratio11.86

Dividend YieldN/A

Beta2.43

Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment develops, manufactures, and sells a range of specialty chemicals derived from co-products of the Kraft pulping process and caprolactone. This segment's products are used in various applications comprising pavement preservation, pavement adhesion promotion and warm mix paving, oil well service additives, oil production and downstream application chemicals, printing inks, adhesives, agrochemicals, lubricants and industrial intermediates, coatings resins, elastomers, adhesives, and bio-plastics. Ingevity Corporation was incorporated in 2015 and is headquartered in North Charleston, South Carolina.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Ingevity has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $73.14, Ingevity has a potential upside of 26.4% from its current price of $57.88.
Amount of Analyst Coverage
Ingevity has only been the subject of 4 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Ingevity has received 348 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ingevity has received 329 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ingevity has received 51.40% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ingevity and other stocks. Vote “Outperform” if you believe NGVT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NGVT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ingevity does not currently pay a dividend.
Dividend Growth
Ingevity does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ingevity insiders have bought more of their company's stock than they have sold. Specifically, they have bought $472,860.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.46% of the stock of Ingevity is held by insiders.
Percentage Held by Institutions
89.87% of the stock of Ingevity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Ingevity are expected to grow by 36.97% in the coming year, from $3.57 to $4.89 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ingevity is 11.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.10.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ingevity is 11.86, which means that it is trading at a less expensive P/E ratio than the Basic Materials sector average P/E ratio of about 23.55.
Price to Book Value per Share Ratio
Ingevity has a P/B Ratio of 4.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.48 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Chemicals & allied products

Sub-IndustryN/A

SectorBasic Materials

Current SymbolNYSE:NGVT

Previous SymbolNASDAQ:NGVT

CUSIPN/A

CIK1653477

Webwww.ingevity.com

Phone843-740-2300

Debt

Debt-to-Equity Ratio2.99

Current Ratio3.49

Quick Ratio2.35

Price-To-Earnings

Trailing P/E Ratio11.86

Forward P/E Ratio16.21

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.29 billion

Price / Sales1.84

Cash Flow$7.57 per share

Price / Cash Flow7.65

Book Value$12.69 per share

Price / Book4.56

Profitability

EPS (Most Recent Fiscal Year)$4.93

Net Income$183.70 million

Net Margins15.82%

Return on Equity45.48%

Return on Assets9.76%

Miscellaneous

Employees1,850

Outstanding Shares41,210,000

Market Cap$2.39 billion

Next Earnings Date7/22/2020 (Estimated)

OptionableOptionable

Receive NGVT News and Ratings via Email

Sign-up to receive the latest news and ratings for NGVT and its competitors with MarketBeat's FREE daily newsletter.

Ingevity (NYSE:NGVT) Frequently Asked Questions

How has Ingevity's stock been impacted by COVID-19 (Coronavirus)?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NGVT shares have increased by 49.2% and is now trading at $57.88. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ingevity?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ingevity.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Ingevity.

How were Ingevity's earnings last quarter?

Ingevity Corp (NYSE:NGVT) released its earnings results on Wednesday, April, 29th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.84 by $0.28. The company earned $288.20 million during the quarter, compared to the consensus estimate of $263.61 million. Ingevity had a net margin of 15.82% and a return on equity of 45.48%. The firm's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.99 earnings per share. View Ingevity's earnings history.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity updated its second quarter 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $246.96-264.6 million, compared to the consensus revenue estimate of $325.64 million.

What price target have analysts set for NGVT?

7 brokers have issued twelve-month target prices for Ingevity's shares. Their forecasts range from $42.00 to $107.00. On average, they anticipate Ingevity's share price to reach $73.14 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price. View analysts' price targets for Ingevity.

Has Ingevity been receiving favorable news coverage?

Press coverage about NGVT stock has trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Ingevity earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutIngevity.

Who are some of Ingevity's key competitors?

Some companies that are related to Ingevity include Johnson Matthey (JMPLY), Huntsman (HUN), Ashland Global (ASH), KURARAY CO LTD/ADR (KURRY), SHOWA DENKO KK/ADR (SHWDY), W. R. Grace & Co (GRA), Balchem (BCPC), Univar (UNVR), Chemours (CC), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM) and Hawkins (HWKN). View all competitors.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), Dominion Energy (D), General Electric (GE), Quaker Chemical (KWR), Boeing (BA), Alibaba Group (BABA) and Walt Disney (DIS).

Who are Ingevity's key executives?

Ingevity's management team includes the following people:

Mr. D. Michael Wilson, Pres, CEO & Director (Age 56)
Mr. John C. Fortson, Exec. VP, CFO & Treasurer (Age 52)
Ms. Katherine Pryor Burgeson, Exec. VP, Gen. Counsel & Sec. (Age 61)
Mr. Stuart Edward Woodcock Jr., Exec. VP & Pres of Performance Materials (Age 53)
Mr. Michael P. Smith, Exec. VP and Pres of Performance Chemicals, Strategy & Bus. Devel. (Age 58)

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (11.48%), Wellington Management Group LLP (3.76%), Franklin Resources Inc. (3.46%), State Street Corp (3.30%), Ardevora Asset Management LLP (2.19%) and Alliancebernstein L.P. (1.90%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Katherine Pryor Burgeson, Michael P Smith, Phillip John Platt and Richard B Kelson. View institutional ownership trends for Ingevity.

Which major investors are selling Ingevity stock?

NGVT stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Victory Capital Management Inc., Wells Fargo & Company MN, Massachusetts Financial Services Co. MA, Wellington Management Group LLP, Russell Investments Group Ltd., BlackRock Inc., and New York State Common Retirement Fund. View insider buying and selling activity for Ingevity.

Which major investors are buying Ingevity stock?

NGVT stock was bought by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Two Sigma Investments LP, Two Sigma Advisers LP, Deutsche Bank AG, Aperture Investors LLC, Canada Pension Plan Investment Board, Rice Hall James & Associates LLC, and Rice Hall James & Associates LLC. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson. View insider buying and selling activity for Ingevity.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $57.88.

How big of a company is Ingevity?

Ingevity has a market capitalization of $2.39 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,850 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

How can I contact Ingevity?

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff